News Medical

An ActRIIA fusion protein got FDA approved for PAH treatment

On March 26th, the US FDA granted approval for Merck’s WINREVAIR™ (sotatercept-csrk), marking a significant milestone in pulmonary arterial hypertension (PAH) treatment. PAH, characterized by elevated ...
Healio

Q&A: Asporin linked to ‘more favorable disease profile’ in patients with PAH

Please provide your email address to receive an email when new articles are posted on . In PAH lung samples, researchers observed elevated asporin levels and found a link between these levels and ...
Healio

Q&A: Yutrepia for PAH, pulmonary hypertension-ILD receives tentative FDA approval

Please provide your email address to receive an email when new articles are posted on . Only one drug has final FDA approval for pulmonary hypertension-ILD; more options are needed. Yutrepia, an ...
The American Journal of Managed Care

FDA Reviewing Sotatercept-csrk Label Expansion for PAH

Sotatercept-csrk received FDA priority review for PAH treatment based on the ZENITH trial's positive results, showing a 76% reduction in major morbidity and mortality events. The ZENITH trial was a ...